Wall Street brokerages predict that MEDNAX Inc (NYSE:MD) will announce $881.50 million in sales for the current quarter, Zacks reports. Eight analysts have provided estimates for MEDNAX’s earnings. The highest sales estimate is $928.24 million and the lowest is $843.18 million. MEDNAX reported sales of $915.92 million during the same quarter last year, which indicates a negative year over year growth rate of 3.8%. The company is expected to issue its next quarterly earnings results on Thursday, August 1st.
On average, analysts expect that MEDNAX will report full-year sales of $3.57 billion for the current financial year, with estimates ranging from $3.46 billion to $3.74 billion. For the next financial year, analysts expect that the business will report sales of $3.73 billion, with estimates ranging from $3.63 billion to $3.92 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover MEDNAX.
MEDNAX (NYSE:MD) last issued its earnings results on Thursday, May 2nd. The company reported $0.58 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.05). The business had revenue of $851.20 million during the quarter, compared to analyst estimates of $906.35 million. MEDNAX had a positive return on equity of 9.82% and a negative net margin of 1.05%. The business’s quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the business earned $0.89 EPS.
A number of equities analysts have recently commented on the company. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Jefferies Financial Group lowered from a “buy” rating to a “hold” rating in a research note on Thursday, April 11th. Finally, Citigroup set a $47.00 price objective on Quanta Services and gave the stock a “buy” rating in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $39.33.
MD traded down $0.09 during trading on Thursday, reaching $24.51. 15,911 shares of the stock traded hands, compared to its average volume of 1,113,262. MEDNAX has a fifty-two week low of $23.05 and a fifty-two week high of $48.77. The firm’s 50-day moving average price is $25.45. The stock has a market cap of $2.15 billion, a PE ratio of 6.96, a price-to-earnings-growth ratio of 0.98 and a beta of 0.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.55 and a current ratio of 2.55.
Several institutional investors and hedge funds have recently made changes to their positions in MD. Riverhead Capital Management LLC lifted its holdings in MEDNAX by 97.1% during the 1st quarter. Riverhead Capital Management LLC now owns 128,689 shares of the company’s stock worth $3,496,000 after buying an additional 63,413 shares in the last quarter. Paradigm Capital Management Inc. NY raised its position in shares of MEDNAX by 3.8% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 37,380 shares of the company’s stock valued at $1,016,000 after acquiring an additional 1,380 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of MEDNAX by 61.2% during the 1st quarter. JPMorgan Chase & Co. now owns 281,476 shares of the company’s stock valued at $7,647,000 after acquiring an additional 106,840 shares during the last quarter. Tyers Asset Management LLC raised its position in shares of MEDNAX by 15.0% during the 1st quarter. Tyers Asset Management LLC now owns 113,960 shares of the company’s stock valued at $3,096,000 after acquiring an additional 14,840 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of MEDNAX during the 4th quarter valued at $34,138,000. 91.14% of the stock is currently owned by institutional investors and hedge funds.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Featured Article: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.